Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Category: CD as API

September 28, 2023 CD as API / Drug delivery / Pharma applications

Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis

A disorder of cholesterol homeostasis is one of the main initiating factors in the progression of atherosclerosis (AS). Metabolism and

Continue reading

September 27, 2023 CD as API / Pharma applications

Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins

Despite advancements in contemporary therapies, cardiovascular disease from atherosclerosis remains a leading cause of mortality worldwide. Supported lipid bilayers (SLBs)

Continue reading

September 25, 2023 CD as API / Drug delivery / Pharma applications

Application of Cyclodextrin for Cancer Immunotherapy

Tumor immunotherapy, compared with other treatment strategies, has the notable advantage of a long-term therapeutic effect for preventing metastasis and

Continue reading

September 21, 2023 CD as API / CD derivatives / Pharma applications / Uncategorized

Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment

Cyclodextrins (CDs), the therapeutic candidates for Niemann–Pick disease type C (NPC), function dually as a shuttle and sink that catalytically

Continue reading

September 20, 2023 CD as API / Pharma applications

PhD and post-doctoral fellowships

Up to 12 fully funded PhD positions have been offered to highly motivated and talented researchers at the Cologne Graduate

Continue reading

July 26, 2023 CD as API / Pharma applications

The Use of Sugammadex as Rescue Therapy Following Inadequate Reversal With Neostigmine – Clinical trial

Neuromuscular blocking agents (NMBAs) are commonly used in the practice of anesthesiology for skeletal muscle relaxation to facilitate tracheal intubation,

Continue reading

July 25, 2023 CD as API / Pharma applications

Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) in Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial

Niemann-Pick disease type C (NPC) is a rare, fatal, pan-ethnic, autosomal recessive lysosomal storage disease characterized by progressive major organ

Continue reading

July 21, 2023 CD as API / Pharma applications

Remembering Dr. David Begley

With immense sadness we have to announce that an outstanding Scientist, Dr. David Begley passed away on Thursday 6th July

Continue reading

July 20, 2023 CD as API / Drug delivery / Pharma applications / Uncategorized

Non-alcoholic Fatty Liver Disease and Cyclodextrins

 Non-alcoholic fatty liver disease and Cyclodextrins Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with no

Continue reading

July 4, 2023 CD as API / CD derivatives / Pharma applications

Lysosomal Targeting of β-Cyclodextrin

β-Cyclodextrin (β-CD) and derivatives are approved therapeutics in >30 clinical settings. β-CDs have also shown promise as therapeutics for treatment

Continue reading

Posts navigation

1 2 3 … 23 Next Posts»

Recent Posts

  • Cyclodextrin related patent application of 2023 Nobel laureate Katalin Karikó
  • Cyclodextrin in Vaccines
  • Special Issue “New Advances in Green Extraction Technology for Natural Products”
  • Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis
  • Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins

Tags

alpha-CD Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food Gilead HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (17)
  • Analysis (39)
  • CD as API (229)
  • CD derivatives (287)
  • Cosmetics and toilettry (22)
  • Diagnosis (2)
  • Drug delivery (499)
  • E-ducation (59)
  • Environmental (84)
  • Events (167)
  • Food (138)
  • Gene delivery (12)
  • In Hungarian (4)
  • Life sciences (21)
  • Non-pharma applications (250)
  • Other industrial use (74)
  • Pharma applications (783)
  • Supramolecular systems (30)
  • Uncategorized (56)

Top Posts

  • Cyclodextrin in Vaccines
  • BioNTech's new invention: CD as potential cryoprotectant in lipid-based RNA formulation
  • Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins
  • Australian company pioneering Cavadextrin for regression of atherosclerosis
  • Cyclodextrin related patent application of 2023 Nobel laureate Katalin Karikó
  • Lanosterol eye drops for cataract treatment
  • Ashland webinar — the magic rings: how cyclodextrins can enable drug development
  • How air fresheners work?
  • Curcumin/amphiphilic cyclodextrin nanoassemblies: Theoretical andspectroscopic studies to address their debut in anticancer therapy
  • HPBCD in an approved non-replicating adenoviral vector-based gene therapy product

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 565 other subscribers
 

Loading Comments...